Apellis Pharmaceuticals Inc (NASDAQ:APLS)’s traded shares stood at 1.88 million during the last session, with the company’s beta value hitting 0.95. At the close of trading, the stock’s price was $47.51, to imply a decrease of -1.08% or -$0.52 in intraday trading. The APLS share’s 52-week high remains $94.75, putting it -99.43% down since that peak but still an impressive 58.26% since price per share fell to its 52-week low of $19.83. The company has a valuation of $5.73B, with an average of 1.37 million shares over the past 3 months.
Apellis Pharmaceuticals Inc (NASDAQ:APLS) trade information
After registering a -1.08% downside in the last session, Apellis Pharmaceuticals Inc (APLS) has traded red over the past five days. The stock hit a weekly high of 55.60, dropping -1.08% in its intraday price action. The 5-day price performance for the stock is -14.75%, and -16.53% over 30 days. With these gigs, the year-to-date price performance is -20.63%.
Apellis Pharmaceuticals Inc (APLS) estimates and forecasts
Looking at statistics comparing Apellis Pharmaceuticals Inc share performance against respective industry, we note that the company has outperformed competitors. Apellis Pharmaceuticals Inc (APLS) shares are 1.56% up over the last 6 months, with its year-to-date growth rate higher than industry average at 70.11% against 13.10%. Revenue is forecast to grow 64.70% this quarter before jumping 63.70% for the next one. The rating firms project that company’s revenue will grow 100.70% compared to the previous financial year.
Revenue forecast for the current quarter as set by 14 analysts is $161.78 million. Meanwhile, for the quarter ending Jun 2024, a total of 14 analyst(s) estimate revenue growth to $187.99 million.Earnings reports from the last fiscal year show that sales brought in $44.85 million and $70.25 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 260.70% before jumping 167.60% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -13.70% for the past 5-year period. While 2024 is set for a 80.24% return in earnings, projections for the next 5 years are at 33.30% annually.
APLS Dividends
Apellis Pharmaceuticals Inc has its next earnings report out in May. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Apellis Pharmaceuticals Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
